Molecules · 2019 · 33 citations · 39 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryMolecular OncologyHematologic Malignancy TherapyMultiple MyelomaOncology PharmacologyAnticancer ActivityCell Viability AssaysCrude Extract PreparationMultiple Myeloma TherapyMultiple Myeloma TreatmentNeurotoxicityPharmacological ScreeningSecondary Metabolites
Multiple myeloma (MM) belongs to hematological cancers and its incidence is increasing worldwide. Despite recent advances in its therapy, MM still causes many deaths every year. In fact, current therapies sometimes fail and are associated with severe adverse effects, including neurotoxicity. As a part of our ongoing efforts to discover new potential therapies against MM, we prepared Hibiscus sabdariffa extracts obtained by a microwave-assisted solvent extraction and investigate their activity by in vitro assays on the RPMI-8226 cell line. The bioguided fractionation of the crude ethanolic extract allowed the identification of HsFC as the most effective extract. We assessed cell viability (MTT and Tripan blue test), cell migration (Boyden chamber assay), and neurotoxicity (DRG neurotoxicity assay). The promising results prompted us to further fractionate HsFC and we obtained two molecules effective against RPMI-8226 cells without neurotoxic effects at their active concentrations. Moreover, both compounds are able to significantly reduce cell migration.
39
Drug resistance in multiple myeloma
Paweł Robak, Izabela Dróźdż, Janusz Szemraj et al. · Cancer Treatment Reviews · 2018 · 290 citations
Medicine, Oncology, Pharmacology +12
Allogeneic transfusion and infection: economic and clinical implications.
P Sonneveld, H M Lokhorst, Paula J.M. Vossebeld · PubMed · 1997 · 273 citations
Medicine, Oncology, Pharmacology +14